These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 17387214)

  • 41. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis.
    Walsh NM; Casano AA; Manangan LP; Sinkowitz-Cochran RL; Jarvis WR
    J Pediatr; 2002 Oct; 141(4):512-7. PubMed ID: 12378190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of Helicobacter pylori infection in patients with cystic fibrosis.
    Drzymała-Czyż S; Kwiecień J; Pogorzelski A; Rachel M; Banasiewicz T; Pławski A; Szczawińska-Popłonyk A; Herzig KH; Walkowiak J
    J Cyst Fibros; 2013 Dec; 12(6):761-5. PubMed ID: 23375733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
    Parkins MD; Elborn JS
    J Antimicrob Chemother; 2010 Sep; 65(9):1853-61. PubMed ID: 20605846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation.
    Etherington C; Naseer R; Conway SP; Whitaker P; Denton M; Peckham DG
    J Cyst Fibros; 2014 Jan; 13(1):49-55. PubMed ID: 23891398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis.
    Schwarz C; Bouchara JP; Buzina W; Chrenkova V; Dmeńska H; de la Pedrosa EGG; Cantón R; Fiscarelli E; Le Govic Y; Kondori N; Matos T; Romanowska E; Ziesing S; Sedlacek L
    Mycopathologia; 2018 Feb; 183(1):7-19. PubMed ID: 29098487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group.
    Schöni MH; Maisonneuve P; Schöni-Affolter F; Lowenfels AB
    J R Soc Med; 1996; 89 Suppl 27(Suppl 27):38-43. PubMed ID: 8778449
    [No Abstract]   [Full Text] [Related]  

  • 47. The changing microbial epidemiology in cystic fibrosis.
    Lipuma JJ
    Clin Microbiol Rev; 2010 Apr; 23(2):299-323. PubMed ID: 20375354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The changing epidemiology of cystic fibrosis.
    FitzSimmons SC
    Curr Probl Pediatr; 1994; 24(5):171-9. PubMed ID: 8070278
    [No Abstract]   [Full Text] [Related]  

  • 49. Potential benefits of the UK Cystic Fibrosis Database.
    Mehta G; Sims EJ; Culross F; McCormick JD; Mehta A
    J R Soc Med; 2004; 97 Suppl 44(Suppl 44):60-71. PubMed ID: 15239297
    [No Abstract]   [Full Text] [Related]  

  • 50. Epidemiology of Cystic Fibrosis.
    Spoonhower KA; Davis PB
    Clin Chest Med; 2016 Mar; 37(1):1-8. PubMed ID: 26857763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.
    Skolnik K; Quon BS
    F1000Res; 2018; 7():. PubMed ID: 29862015
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cancer risk among patients with cystic fibrosis.
    Neglia JP; Wielinski CL; Warwick WJ
    J Pediatr; 1991 Nov; 119(5):764-6. PubMed ID: 1941382
    [No Abstract]   [Full Text] [Related]  

  • 53. Understanding and managing poor adherence in cystic fibrosis.
    Lask B
    Pediatr Pulmonol Suppl; 1997; 16():260-1. PubMed ID: 9443303
    [No Abstract]   [Full Text] [Related]  

  • 54. Isolation of Sporosarcina ureae from a bronchial biopsy in a child with cystic fibrosis.
    Chomarat M; de Montclos M; Flandrois JP; Breysse F
    Eur J Clin Microbiol Infect Dis; 1990 Apr; 9(4):302-3. PubMed ID: 2351147
    [No Abstract]   [Full Text] [Related]  

  • 55. Pulmonary exacerbations in cystic fibrosis.
    Stenbit AE; Flume PA
    Curr Opin Pulm Med; 2011 Nov; 17(6):442-7. PubMed ID: 21881509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
    Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
    Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
    de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
    Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
    Flume PA; Mogayzel PJ; Robinson KA; Goss CH; Rosenblatt RL; Kuhn RJ; Marshall BC;
    Am J Respir Crit Care Med; 2009 Nov; 180(9):802-8. PubMed ID: 19729669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
    Sanders DB; Bittner RC; Rosenfeld M; Redding GJ; Goss CH
    Pediatr Pulmonol; 2011 Apr; 46(4):393-400. PubMed ID: 20967845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.